Table 2. Investigator-assessed treatment response in ITT and ITT EGFR-WT populations†.
| Response | n (%) | ||||
| ITT | ITT EGFR-WT | ||||
| Atezolizumab (N=375) | Docetaxel (N=188) | Atezolizumab (N=311) | Docetaxel (N=155) | ||
| ITT, intention to treat; EGFR, epidermal growth factor receptor; WT, wild type; DOR, duration of response. †, Patients with measurable diseases at baseline. | |||||
| Responders | 48 (12.8) | 19 (10.1) | 47 (15.1) | 10 (6.5) | |
| Complete response | 1 (0.3) | 0 (0) | 1 (0.3) | 0 (0) | |
| Partial response | 47 (12.5) | 19 (10.1) | 46 (14.8) | 10 (6.5) | |
| Stable disease | 162 (43.2) | 66 (35.1) | 131 (42.1) | 61 (39.4) | |
| Progressive disease | 133 (35.5) | 59 (31.4) | 105 (33.8) | 48 (31.0) | |
| DOR (month) | 48 | 19 | 47 | 10 | |
| Median | 18.4 | 4.6 | 19.8 | 4.4 | |